Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti* suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need. Source
No articles found.
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...
Iovance Biotherapeutics (formerly traded as Lio...
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...
WuXi Biologics (stock code: 2269.HK), a Hong Ko...
Anavex utilizes precision genetic medicine to treat severe and devastating neurolo...
Anavex utilizes precision genetic medicine to t...
Join the National Investor Network and get the latest information with your interests in mind.